FDA Calendar

Company Name CTI BioPharma Corp.
Drug Name PIXUVRI (NDA resubmission)
Event Name FDA decision on PIXUVRI (pixantrone) to treat relapsed or refractory aggressive non-Hodgkin's lymphoma in patients
Event Date 04/24/2012
Outcome Date
Outcome PIXUVRI NDA voluntarily withdrawn by company. To be resubmitted in 2012
Drug Status
Rival Drugs
Market Potential
Other Approvals
Cell Therapeutics' NDA For Pixantrone Given PDUFA Goal Date By FDA - Quick Facts
Cell Therapeutics - Poised For Tough Battle Or Smooth Ride?
Cell Therapeutics Voluntarily Withdraws Its NDA For Pixuvri - Quick Facts
Return to FDA Calendar